🔗 Share this article

While the US undertakes historic revisions to its immunization guidelines, one figure has emerged somewhat surprisingly: Tracy Beth Høeg, a US-based physician and public health researcher who initially gained attention by expressing skepticism about COVID-19 shots in the pandemic and has zeroed in on alleged fatalities following COVID-19 immunization in her recent tenure at the FDA.

Scheduled Shifts to Pediatric Vaccine Schedule

Health officials were set to reveal major changes to the pediatric immunization program recently, synchronizing the US with Denmark’s vaccine program, it is understood – a major change that would place the US out of step with a large portion of the global community with no evidence for improved outcomes. The planned update has been pushed back until the new year.

Instead of the top vaccines chief, Dr. Høeg is scheduled to speak at the meeting. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth appointee to lead the office this year.

A New Direction at the Agency

The acting appointment could signify a closer partnership between the drug and biologics divisions as Dr. Høeg and Prasad consolidate power at the FDA – and it suggests a increased emphasis upon reevaluating already-approved vaccines at the FDA.

The new acting director has often pushed for ending certain pediatric vaccine recommendations in the US so as to align more in line with Denmark's approach, a nation with nationalized medicine and a number of inhabitants about the size of the state of Wisconsin.

So far statements, she has continued to focus on vaccination policy – traditionally the domain of Prasad, head of the FDA’s vaccine center – as opposed to medication approval.

Doubts Over Qualifications

Dr. Høeg has little discernible track record in pharmaceutical research, regulation or management, which has been standard for past heads of the biologics center. She has served at the FDA as a top consultant to the agency head and the vaccine center since March.

“She doesn’t seem to have the requisite experience” for overseeing the CDER, said Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in running a sizeable institution. She has no expertise in pharmaceutical oversight.”

Previous heads of CBER would “grasp regulatory frameworks and the science of medication creation”, noted Dr. Janet Woodcock. “Objectively, she lacks the type of experience that former directors who headed CBER have had.”

CDER has an enormous portfolio at the FDA, the former commissioner pointed out.

“The public just pays attention on the novel medication approvals, but the generic program clears thousands of generic medications. There’s a biologic copycat branch, OTC medication office and more, and each of these must be supervised,” Dr. Woodcock explained. “The thing you overlook, that is the part that I always told people is going to bite you.”

Furthermore, a substantial management component to the position, which oversees over 5,000 personnel. “It’s a massive administrative position, if you perform it correctly,” Woodcock said.

Response and Controversial Policies

In response to concerns about Høeg’s qualifications and whether this selection represents increased cooperation among FDA leaders on vaccines, a press secretary responded that the “concerns stem from inaccurate presumptions”.

“Her resume is consistent with the duties of her job,” the representative explained, pointing to the period Dr. Høeg spent counseling the agency head on “drug safety and oversight research, including computerized risk analysis and immunization monitoring”.

As acting director, Høeg assumes responsibility for the agency head's controversial fast-track approval initiative, a contentious expedited therapy clearance system that allegedly worried her preceding directors. “How are these medications being picked for this voucher program? Who takes the calls?” Howard asked. “There is a lot of lack of transparency happening at the regulatory body right now.”

Broadly speaking, he stated, “the agency looks to be trending towards more relaxed oversight of all drugs, with the exception of immunizations.”

Documented Past Work on Vaccines

Concerning vaccines, Dr. Høeg has a clearer, if problematic, track record, some experts said. She authored a research paper using non-validated public submissions to estimate the rate of heart inflammation after Covid vaccination. She counseled the Florida surgeon general Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccinations are pose a greater threat than they are.

Included in her “wish list” for the new federal leadership featured revising regulations for new vaccines and halting “optional” immunizations, she remarked post-election on a audio program. At the FDA, Høeg has allegedly proposed preventing adolescent males from getting COVID-19 vaccines.

“She is an thorough ideologue who begins with her conclusions and reverse-engineers to accommodate the science in a very disingenuous, dishonest way,” Howard stated.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with fellow skeptics, {like|